Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT00726232
Other study ID # INCB 18424-256
Secondary ID Ruxolitinib
Status Terminated
Phase Phase 2
First received
Last updated
Start date August 20, 2008
Est. completion date August 20, 2018

Study information

Verified date October 2019
Source Incyte Corporation
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To evaluate the safety and efficacy profile of different treatment regimens of Ruxolitinib (INCB018424) administered to two groups of patients; those with polycythemia vera (PV) and those with essential thrombocythemia (ET). Patients in each group were refractory to hydroxyurea or for whom hydroxyurea is contraindicated.


Description:

The study consisted of a 2-stage design, which included a dose-ranging phase (during which patients received treatment at their randomized dose) and an expansion phase (after adjustment of dose/regimen to achieve an optimal balance of efficacy and safety). During the dose-ranging phase, patients in each disease group (PV or ET) were randomly assigned in a 1:1:1 ratio independent of each other to receive 1 of 3 treatment regimens with Ruxolitinib, 10 mg twice daily (bid), 25 mg bid, or 50 mg once daily (qd). After patients completed 2 cycles of treatment with Ruxolitinib at the randomized dose, Investigators were permitted to adjust the dose/regimen on an individual basis using their discretion in order to achieve an optimal balance of efficacy and safety. During the expansion phase (ie, after optimization of dose), additional patients with PV or ET were enrolled to receive Ruxolitinib at the dose that was selected upon review of data from the dose-ranging phase. Treatment continued until a patient met a withdrawal criterion, had intolerable toxicity, progression of disease, or withdrew consent.


Recruitment information / eligibility

Status Terminated
Enrollment 73
Est. completion date August 20, 2018
Est. primary completion date June 20, 2010
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Confirmed diagnosis of polycythemia vera or essential thrombocythemia as determined by treating physician

- Disease refractory to hydroxyurea or for whom treatment with hydroxyurea is contraindicated or have refused further treatment with hydroxyurea due to side effects.

- Patient meets baseline clinical lab parameters

Exclusion Criteria:

- Treatment with interferon alpha or anagrelide within 7 days and hydroxyurea within 1 day of starting INCB018424.

- Patients diagnosed with another malignancy unless the malignancy was cervical intraepithelial neoplasia or basal or squamous cell skin cancer and the patient has been disease free for > 3 years

- Patients receiving therapy with intermediate or high dose steroids greater than the equivalent of 10 mg prednisone per day

- Clinically significant cardiac disease (New York Heart Association (NYHA) Class III or IV)

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Ruxolitinib
Ruxolitinib was administered orally and supplied as 5 mg and 25 mg tablets.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Incyte Corporation

Countries where clinical trial is conducted

United States,  Italy, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of Polycythemia Vera Participants With a Confirmed Clinical Partial Response (PR) or Complete Response (CR) For a confirmed response all criteria must have been sustained for at least 2 months.
CR:
Hematocrit < 45% in men and < 42% in women
No phlebotomy for 1 month
No palpable splenomegaly
White blood cells < 10 x 10^9/L with normal differential and platelets < 400 x 10^9/L
No sustained leucopenia or thrombocytopenia (>2 weeks)
No systemic PV symptoms (pruritus, night sweats, bone pain, fever, weight loss)
PR:
Hematocrit < 45% in men and < 42% in women
50% reduction in phlebotomy requirements from 6 months before treatment started
50% reduction in palpable splenomegaly
Assessed after 2 cycles (56 days) of treatment on Day 1 of Cycle 3
Primary Percentage of Essential Thrombocythemia (ET) Participants With a Confirmed Clinical Partial Response (PR) or Complete Response (CR) For a confirmed response all criteria must have been sustained for at least 2 months.
Complete Clinical Response:
Platelet count < 400 x 10^9/L
White blood cell count < 10 x 10^9/L with normal differential and Hematocrit = upper limit of normal
Absence of sustained (> 2 weeks) anemia or leucopenia based on institutional normal ranges
Absence of systemic ET symptoms (pruritus, bone pain, weakness, night sweats, paresthesias)
Absence of palpable splenomegaly
Partial Clinical Response:
Platelet count < 400 x 10^9/L
50% reduction in palpable splenomegaly
Assessed after 2 cycles (56 days) of treatment on Day 1 of Cycle 3.
Secondary Percentage of Polycythemia Vera Participants Who Achieved Individual Components of Clinical Response at 12 Weeks The individual components of clinical response included:
Hematocrit (Hct) < 45% without phlebotomy
Absence of palpable splenomegaly
50% reduction in spleen size
Platelet count = 400 x 10^9/L
White blood cell (WBC) count = 10 x 10^9/L
Baseline and Week 12 (Cycle 4, Day 1)
Secondary Percentage of Polycythemia Vera Participants Who Achieved Individual Components of Clinical Response at 24 Weeks The individual components of clinical response included:
Hematocrit (Hct) < 45% without phlebotomy
Absence of palpable splenomegaly
50% reduction in spleen size
Platelet count = 400 x 10^9/L
White blood cell (WBC) count = 10 x 10^9/L
Baseline and Week 24 (Cycle 7, Day 1)
Secondary Percentage of Polycythemia Vera Participants Who Achieved Individual Components of Clinical Response at 36 Weeks The individual components of clinical response included:
Hematocrit (Hct) < 45% without phlebotomy
Absence of palpable splenomegaly
50% reduction in spleen size
Platelet count = 400 x 10^9/L
White blood cell (WBC) count = 10 x 10^9/L
Baseline and Week 36 (Cycle 10, Day 1)
Secondary Percentage of Essential Thrombocythemia Participants Who Achieved Individual Components of Clinical Response at 4 Weeks The individual components of clinical response included:
Platelet count = 400 x 10^9/L
White blood cell (WBC) count = 10 x 10^9/L
50% reduction in spleen size
Absence of palpable splenomegaly
Baseline and 4 weeks (Cycle 2, Day 1)
Secondary Percentage of Essential Thrombocythemia Participants Who Achieved Individual Components of Clinical Response at 24 Weeks The individual components of clinical response included:
Platelet count = 400 x 10^9/L
White blood cell (WBC) count = 10 x 10^9/L
50% reduction in spleen size
Absence of palpable splenomegaly
Baseline and 24 weeks (Cycle 7, Day 1)
Secondary Percentage of Essential Thrombocythemia Participants Who Achieved Individual Components of Clinical Response at 36 Weeks The individual components of clinical response included:
Platelet count = 400 x 10^9/L
White blood cell (WBC) count = 10 x 10^9/L
50% reduction in spleen size
Absence of palpable splenomegaly
Baseline and 36 weeks (Cycle 10, Day 1)
Secondary Change From Baseline to Week 4 in Polycythemia Vera Symptoms Patients were asked to rate their symptoms on a scale of 0 (none) to 10 (worse possible) for the prior week giving the worst level of symptoms experienced during the preceding 7 days. A negative change from baseline score indicates improvement in symptoms.
For patients with Polycythemia Vera, queried symptoms included fever, itching/pruritus, bone pain and night sweats.
Baseline and Week 4 (Cycle 2, Day 1)
Secondary Change From Baseline to Week 4 in Essential Thrombocythemia Symptoms Patients were asked to rate their symptoms on a scale of 0 (none) to 10 (worse possible) for the prior week giving the worst level of symptoms experienced during the preceding 7 days. A negative change from baseline score indicates improvement in symptoms.
For patients with essential thrombocythemia, queried symptoms included itching/pruritus, bone pain, night sweats, paresthesias (tingling or numbness), and weakness.
Baseline and Week 4 (Cycle 2, Day 1)
Secondary Change From Baseline to Week 4 in Health-related Quality of Life Health-related Quality of Life was assessed using the Global Health Status/Quality of Life Scale of the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30). This scale ranges from 0 to 100, with higher scores indicating higher quality of life. Baseline and Week 4 (Cycle 2, Day 1)
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05115344 - Study of Flonoltinib Maleate Tablets in the Treatment of Proliferative Bone Marrow Tumors Phase 1
Recruiting NCT05153343 - Safety of Flunotinib Maleate Tablets for the Treatment of Patients With Myeloproliferative Phase 1/Phase 2
Completed NCT04243122 - Assessing Feasibility of Thromboprophylaxis With Apixaban in JAK2-positive Myeloproliferative Neoplasm Patients Phase 2